Acute Profound Thrombocytopenia after Using Abciximab for No-Reflow during Primary Percutaneous Coronary Intervention for ST-Segment Elevation Myocardial Infarction
Korean Circulation Journal
; : 557-560, 2013.
Article
in En
| WPRIM
| ID: wpr-24540
Responsible library:
WPRO
ABSTRACT
Glycoprotein IIb/IIIa antagonists are well established for their effectiveness in improving clinical outcomes in acute coronary syndrome patients undergoing percutaneous coronary intervention. Acute profound thrombocytopenia is a rare complication of abciximab. We present a case which was managed successfully for the rare complication of acute profound thrombocytopenia after using abciximab and an intra-aortic balloon pump for the treatment of a no-reflow phenomenon and consecutive cardiogenic shock during primary percutaneous coronary intervention.
Key words
Full text:
1
Database:
WPRIM
Main subject:
Shock, Cardiogenic
/
Thrombocytopenia
/
Immunoglobulin Fab Fragments
/
Acute Coronary Syndrome
/
No-Reflow Phenomenon
/
Percutaneous Coronary Intervention
/
Antibodies, Monoclonal
/
Myocardial Infarction
Limits:
Humans
Language:
En
Journal:
Korean Circulation Journal
Year:
2013
Document type:
Article